Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2.
作者信息
Orgel Kelly A, Duan Shiteng, Wright Benjamin L, Maleki Soheila J, Wolf John C, Vickery Brian P, Burks A Wesley, Paulson James C, Kulis Mike D, Macauley Matthew S
机构信息
Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC; UNC Food Allergy Initiative, Chapel Hill, NC; Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC.
Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, Calif; Department of Chemical Physiology, The Scripps Research Institute, La Jolla, Calif; Department of Immunology and Microbial Sciences, The Scripps Research Institute, La Jolla, Calif.
出版信息
J Allergy Clin Immunol. 2017 Jan;139(1):366-369.e2. doi: 10.1016/j.jaci.2016.06.053. Epub 2016 Aug 20.
Abstract
摘要
相似文献
1
Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2.
J Allergy Clin Immunol. 2017 Jan;139(1):366-369.e2. doi: 10.1016/j.jaci.2016.06.053. Epub 2016 Aug 20.
2
Home-based induction of sustained unresponsiveness in children with mild reactions to high doses of peanut.
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1757-1759. doi: 10.1016/j.jaip.2017.03.027. Epub 2017 Apr 29.
3
Peanut oral immunotherapy decreases IgE to Ara h 2 and Ara h 6 but does not enhance sensitization to cross-reactive allergens.
J Allergy Clin Immunol. 2017 Apr;139(4):1393-1396.e6. doi: 10.1016/j.jaci.2016.09.054. Epub 2016 Dec 1.
4
A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy.
Allergy. 2013 Jun;68(6):803-8. doi: 10.1111/all.12158. Epub 2013 Apr 29.
5
An unfolded variant of the major peanut allergen Ara h 2 with decreased anaphylactic potential.
Clin Exp Allergy. 2012 Dec;42(12):1801-12. doi: 10.1111/cea.12031.
6
Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects.
J Allergy Clin Immunol. 2015 Jul;136(1):125-134.e12. doi: 10.1016/j.jaci.2015.03.026. Epub 2015 May 16.
7
New routes of allergen immunotherapy.
Allergol Immunopathol (Madr). 2017 Dec;45 Suppl 1:39-40. doi: 10.1016/j.aller.2017.09.010. Epub 2017 Nov 10.
8
Single B-cell deconvolution of peanut-specific antibody responses in allergic patients.
J Allergy Clin Immunol. 2016 Jan;137(1):157-167. doi: 10.1016/j.jaci.2015.05.029. Epub 2015 Jul 4.
9
Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice.
J Allergy Clin Immunol. 2013 Jan;131(1):213-21.e1-5. doi: 10.1016/j.jaci.2012.10.018. Epub 2012 Nov 27.
10
Lactobacillus buchneri S-layer as carrier for an Ara h 2-derived peptide for peanut allergen-specific immunotherapy.
Mol Immunol. 2017 May;85:81-88. doi: 10.1016/j.molimm.2017.02.005. Epub 2017 Feb 14.
引用本文的文献
1
Nanoparticle-Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology.
Angew Chem Int Ed Engl. 2025 May 5:e202503958. doi: 10.1002/anie.202503958.
2
Induced proximity at the cell surface.
Nat Biotechnol. 2025 May;43(5):702-711. doi: 10.1038/s41587-025-02592-1. Epub 2025 Mar 26.
3
Allergen-specific B cell responses in oral immunotherapy-induced desensitization, remission, and natural outgrowth in cow's milk allergy.
Allergy. 2025 Jan;80(1):161-180. doi: 10.1111/all.16220. Epub 2024 Jul 11.
4
Chemical immunology: Recent advances in tool development and applications.
Cell Chem Biol. 2024 Mar 13. doi: 10.1016/j.chembiol.2024.02.006.
5
Biomaterial engineering strategies for B cell immunity modulations.
Biomater Sci. 2024 Apr 16;12(8):1981-2006. doi: 10.1039/d3bm01841e.
6
CD22L Conjugation to Insulin Attenuates Insulin-Specific B Cell Activation.
Bioconjug Chem. 2023 Nov 15;34(11):2077-2088. doi: 10.1021/acs.bioconjchem.3c00391. Epub 2023 Oct 26.
7
Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases.
Semin Immunol. 2023 Sep;69:101799. doi: 10.1016/j.smim.2023.101799. Epub 2023 Jul 4.
8
Glycomimetics for the inhibition and modulation of lectins.
Chem Soc Rev. 2023 Jun 6;52(11):3663-3740. doi: 10.1039/d2cs00954d.
9
Impact of Siglecs on autoimmune diseases.
Mol Aspects Med. 2023 Apr;90:101140. doi: 10.1016/j.mam.2022.101140. Epub 2022 Aug 30.
10
Targeting CD22 on memory B cells to induce tolerance to peanut allergens.
J Allergy Clin Immunol. 2022 Dec;150(6):1476-1485.e4. doi: 10.1016/j.jaci.2022.06.022. Epub 2022 Jul 14.
本文引用的文献
1
Heterogeneous responses and cross reactivity between the major peanut allergens Ara h 1, 2,3 and 6 in a mouse model for peanut allergy.
Clin Transl Allergy. 2015 Mar 23;5:13. doi: 10.1186/s13601-015-0056-9. eCollection 2015.
2
Suppression of the immunologic response to peanut during immunotherapy is often transient.
J Allergy Clin Immunol. 2015 May;135(5):1283-92. doi: 10.1016/j.jaci.2014.11.010. Epub 2014 Dec 24.
3
Siglec-mediated regulation of immune cell function in disease.
Nat Rev Immunol. 2014 Oct;14(10):653-66. doi: 10.1038/nri3737. Epub 2014 Sep 19.
4
Diagnostic accuracy of specific IgE to components in diagnosing peanut allergy: a systematic review.
Clin Exp Allergy. 2015 Apr;45(4):720-30. doi: 10.1111/cea.12412.
5
State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous.
J Allergy Clin Immunol. 2014 Feb;133(2):318-23. doi: 10.1016/j.jaci.2013.12.1040.
6
Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis.
J Clin Invest. 2013 Jul;123(7):3074-83. doi: 10.1172/JCI69187. Epub 2013 Jun 3.
7
IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3.
J Allergy Clin Immunol. 2013 Jul;132(1):118-24. doi: 10.1016/j.jaci.2013.01.022. Epub 2013 Mar 5.
8
The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice.
Clin Exp Allergy. 2012 Feb;42(2):326-36. doi: 10.1111/j.1365-2222.2011.03934.x.
Zotero 插件